Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
Understanding MASH and the Growing Need for Intervention
Metabolic Dysfunction-Associated Steatohepatitis, or MASH, represents a severe and progressive form of fatty liver disease. Previously known as Non-Alcoholic Steatohepatitis (NASH), the updated terminology reflects a deeper medical understanding that the condition is intrinsically linked to systemic metabolic dysfunction, including obesity, insulin resistance, and type 2 diabetes. MASH is characterized by the accumulation of excess fat in the liver, accompanied by inflammation and cellular damage. Left unchecked, this inflammatory process triggers the formation of scar tissue, known as fibrosis. As fibrosis progresses from stage 2 (moderate) to stage 3 (severe) and eventually stage 4 (cirrhosis), the liver loses its ability to function, often necessitating a transplant or leading to hepatocellular carcinoma. Despite the rising global prevalence of MASH, therapeutic options have historically been limited, focusing primarily on lifestyle interventions which are often difficult for patients to maintain.
The Rise of Tirzepatide as a Dual-Agonist Therapy
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.